Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 5,808.00
+11.00 (0.19%)
Aug 25, 2026, 1:55 PM JST
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.22T JPY in the quarter ending June 30, 2026, with 10.23% growth. This brings the company's revenue in the last twelve months to 4.62T, up 4.57% year-over-year. In the fiscal year ending March 31, 2026, Takeda Pharmaceutical Company had annual revenue of 4.51T, down -1.66%.
Revenue (ttm)
4.62T
Revenue Growth
+4.57%
P/S Ratio
2.00
Revenue / Employee
98.21M
Employees
47,029
Market Cap
9.26T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.85B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.19B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | 326.69B | 18.45% |
| Mar 31, 2018 | 1.77T | 38.48B | 2.22% |
| Mar 31, 2017 | 1.73T | -75.33B | -4.17% |
| Mar 31, 2016 | 1.81T | 29.55B | 1.66% |
| Mar 31, 2015 | 1.78T | 86.14B | 5.09% |
| Mar 31, 2014 | 1.69T | 134.42B | 8.63% |
| Mar 31, 2013 | 1.56T | 48.34B | 3.20% |
| Mar 31, 2012 | 1.51T | 89.55B | 6.31% |
| Mar 31, 2011 | 1.42T | -46.58B | -3.18% |
| Mar 31, 2010 | 1.47T | -72.37B | -4.70% |
| Mar 31, 2009 | 1.54T | 163.53B | 11.90% |
| Mar 31, 2008 | 1.37T | 69.64B | 5.34% |
| Mar 31, 2007 | 1.31T | 92.96B | 7.67% |
| Mar 31, 2006 | 1.21T | 89.25B | 7.95% |
| Mar 31, 2005 | 1.12T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eisai | 857.06B |
| Shionogi & | 563.21B |
| Sumitomo Pharma | 474.79B |
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| Mochida Pharmaceutical | 122.04B |
Takeda Pharmaceutical Company News
- 20 hours ago - Takeda announces Japan MHLW approval for Orzeyful - TheFly
- 22 hours ago - ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 - Business Wire
- 6 days ago - A Look at Takeda Pharmaceutical Co Ltd (TAK) After 3.9% Gain -- GF Value $14.36 vs Price $18.05 - GuruFocus
- 6 days ago - Tuesday's ETF Movers: PPH, PTF - Nasdaq
- 6 days ago - Wall Street Analysts Think Takeda Pharmaceutical Co. (TAK) Could Surge 26.41%: Read This Before Placing a Bet - Nasdaq
- 14 days ago - Takeda award from Veterans Affairs posted to SAM.gov site - TheFly
- 19 days ago - FDA approves Takeda’s Orzeyful to treat narcolepsy type 1 - TheFly
- 19 days ago - U.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 - Business Wire